Transcatheter Aortic Valve-in-Valve Replacement for Degenerated Stentless Bioprosthetic Aortic Valves

Miller, Matt; Snyder, Mandy; Horne, Benjamin D.; Harkness, James; Doty, John R.; Miner, Edward; Jones, Kent W.; O’Neal, Kelly R.; Reid, B.B.; Caine, W.T.; Clayson, Stephen E.; Lindley, Eric; Gardner, Blake; Connors, Rafe C.; Bowles, B. Jason; Whisenant, Brian

doi:10.1016/j.jcin.2019.05.022

Cited by 22 publications

(30 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To add to the misery, the stentless valves commonly sutured to the native aortic roots shorten the distance further. 14) Therefore, in contrast to the native-TAVR, the original device and implantation approach selection may be taken into consideration when assessing the CO risk in VIV-TAVR.…”

Section: Discussionmentioning

confidence: 99%

“…Urgent percutaneous coronary intervention (PCI) was performed in 39 (79.4%) subjects and succeed in 27(69.2%). 26) *** ** ** Akodad, et al 24) *** * ** Camboni, et al 27) *** * ** Ye, et al 28) *** ** ** Grubitzsch, et al 29) **** * *** Schneider , et al 30) *** ** ** Tchétché, et al 31) *** ** ** Miller, et al 14) *** * ** Adamo, et al 13) *** * *** Wernly, et al 32) **** * ** Mosquera, et al 33) *** * *** Ribeiro, et al 10) *** ** ** Webb, et al 34) **** ** **…”

Section: Outcomes Of Co Post-viv-tavrmentioning

confidence: 99%

“…Three studies 10,13,14) incorporating 29 patients with CO and 159 patients without CO were pooled using the univariate analysis method to investigate the computed tomography (CT) measurement predictors of CO post-VIV-TAVR. The sinus of Valsalva (SOV) diameter was narrower in the CO group (27.5 ± 3.8 mm, n = 23 versus 32.3 ± 4.0 mm, n = 101; mean difference, −3.80 mm; 95%CI, −6.55 to −1.05 mm; P = 0.007) (Figure 3A).…”

Section: Risk Factors Of Co Post-viv-tavrmentioning

confidence: 99%

See 2 more Smart Citations

Incidence, Risk Factors, and Outcomes of Coronary Obstruction Following Valve-in-Valve Transcatheter Aortic Valve Replacement

et al. 2021

View full text Add to dashboard Cite

There is scant information about the incidence, risk factors, and outcomes of coronary obstruction (CO) following valve-in-valve transcatheter aortic valve replacement (VIV-TAVR). A meta-analysis of the published studies from January 2000 to April 2020 was conducted, and the endpoint was CO. A total of 2858 patients were enrolled in this study. The mean age was 77.7 ± 9.8, and 39.9% of them were female. The Society of Thoracic Surgeons (STS) score, European System for Cardiac Operative Risk Evaluation (EuroSCORE), and Logistic EuroSCORE were 8.9 ± 7.8, 16.0 ± 10.9, and 26.3 ± 16.3, respectively. The overall incidence of CO was 2.58%. CO incidence between patients with prior stented and stentless valves were significantly different (1.67% versus 7.17%), with an odds ratio (OR) of 0.25 and a 95% confidence interval (CI) of 0.14-0.44 (P < 0.00001). The first-generation valves were significantly associated with higher CO incidence compared with the second-generation valves (7.09% versus 2.03%; OR, 2.44; 95%CI, 1.06-5.62; P = 0.04), while no statistical difference was found between self-expandable valves and balloon-expandable valves (2.45% versus 2.60%; OR, 0.99; 95%CI, 0.55-1.79; P = 0.98). Virtual transcatheter to coronary ostia (VTC) distance (3.3 ± 2.1 mm, n = 29 versus 5.8 ± 2.4 mm, n = 169; mean difference, −2.70; 95%CI, −3.46 to −1.95; P < 0.00001) and the sinus of Valsalva (SOV) diameter (27.5 ± 3.8 mm, n = 23 versus 32.3 ± 4.0 mm, n = 101; mean difference, −3.80; 95%CI, −6.55 to −1.05; P = 0.007) were enormously shorter in patients with CO. The 24-hour, in-hospital, and 30-day mortality of patients with CO were 10.5%, 30.8%, and 37.1%, respectively. In conclusion, device selections, VTC distances, and SOV diameters may be important factors in assessing the CO risk in VIV-TAVR.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Outcomes Of Co Post-viv-tavrmentioning

confidence: 99%

Section: Risk Factors Of Co Post-viv-tavrmentioning

confidence: 99%

See 1 more Smart Citation

Incidence, Risk Factors, and Outcomes of Coronary Obstruction Following Valve-in-Valve Transcatheter Aortic Valve Replacement

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Prosthesis degeneration, valve durability and the need for aortic valve reintervention will also need to be further evaluated in this group of younger patients. Although valve-in-valve procedures have demonstrated encouraging results in patients with degenerated surgical aortic bioprostheses, 36 whether these results can be achieved for valve-in-valve procedures in degenerated TAVI valves remains to be seen.…”

Section: Tavi Valve Durabilitymentioning

confidence: 99%

Transcatheter management of severe aortic stenosis during the COVID-19 pandemic

Khialani

MacCarthy

2020

Heart

View full text Add to dashboard Cite

“…A recent study evaluating the safety and efficacy of TAVR-ViV for stentless bioprosthetic aortic valves showed that subcoronary implant technique, short simulated radial valve-to-coronary distance and low coronary height are predictors of coronary occlusion (17).…”

Section: Incidence Mechanism and Risk Assessment Of Coronary Occlusmentioning

confidence: 99%

How to Avoid Coronary Occlusion During TAVR Valve-in-Valve Procedures

Valvo

Costa

Barbanti

2019

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Transcatheter aortic valve-in-valve replacement has been recently reported as a less-invasive alternative to re-do surgery in patients with bioprosthetic valve failure. Although procedural success is achieved in the great majority of patients, this therapy is associated with several potential complications, and coronary occlusion is one of the most feared. This is a rare event, but it is associated with an extremely poor prognosis. In this review, the mechanisms, the identification of patients at high risk, the primary prevention strategies, and treatment of coronary occlusion will be discussed.

show abstract

Transcatheter Aortic Valve-in-Valve Replacement for Degenerated Stentless Bioprosthetic Aortic Valves

Cited by 22 publications

References 12 publications

Incidence, Risk Factors, and Outcomes of Coronary Obstruction Following Valve-in-Valve Transcatheter Aortic Valve Replacement

Incidence, Risk Factors, and Outcomes of Coronary Obstruction Following Valve-in-Valve Transcatheter Aortic Valve Replacement

Transcatheter management of severe aortic stenosis during the COVID-19 pandemic

How to Avoid Coronary Occlusion During TAVR Valve-in-Valve Procedures

Contact Info

Product

Resources

About